<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cancer survivorship: Cardiovascular and respiratory issues</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cancer survivorship: Cardiovascular and respiratory issues</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cancer survivorship: Cardiovascular and respiratory issues</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bonnie Ky, MD, MSCE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lavanya Kondapalli, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Lenihan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia A Ganz, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H21065926"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>With the success of modern cancer therapy, cancer can be curable, and in cases where cure cannot be achieved, it is commonly treated as a chronic disease. As a result, there are approximately 44 million cancer survivors worldwide [<a href="#rid1">1</a>], and this number is expected to increase over time [<a href="#rid2">2</a>]. It has also become apparent that cardiovascular (CV) disease, in general, is the major life-limiting comorbidity in patients previously treated for cancer who survive beyond five years [<a href="#rid3">3</a>]. Given the growing population of patients once treated (or continuing treatment) for cancer, the medical community must learn how to best optimize CV health and minimize the CV complications of cancer treatment.</p><p>A growing population of adult survivors of both pediatric and adult-onset cancers are recognized to have an increased incidence of: CV risk factors (hypertension [HTN], dyslipidemia, diabetes, obesity), CV disease (coronary disease, valvular disease, cardiomyopathy, heart failure [HF], and stroke) [<a href="#rid3">3-5</a>], and pulmonary disease compared with the general population [<a href="#rid6">6,7</a>]. Epidemiologic data suggest that common CV risk factors are more strongly associated with risk of incident CV disease in cancer survivors as compared with noncancer controls [<a href="#rid8">8</a>]. Because of the potential for these conditions to result in a high degree of morbidity and mortality, understanding how to improve the prevention, recognition, and treatment of CV and pulmonary disease is an important priority to the overall health of this population.</p><p>This section will focus on the long-term CV complications encountered in cancer survivorship and will also cover respiratory issues related to cancer therapy. Since there are a myriad of possible complications of cancer therapy [<a href="#rid9">9</a>], this section will summarize the most important and common cardiopulmonary conditions related to these systems. In each subsection, the diagnosis, treatment, and prognosis will be highlighted, if known, and areas where improvements in understanding are needed will be outlined. Finally, practical recommendations will be made for certain principles that may help guide the optimal treatment of CV effects in cancer survivors.</p><p>For readers who desire a broader overview of cancer survivorship, a separate topic that discusses these issues is available. (See  <a class="medical medical_review" href="/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers"</a>.)</p><p class="headingAnchor" id="H21065932"><span class="h1">ATHEROSCLEROSIS</span></p><p class="headingAnchor" id="H2268724428"><span class="h2">Effect of cancer therapy on atherosclerosis</span><span class="headingEndMark"> — </span>Various cancer therapies are associated with increased atherosclerosis, such as radiation therapy (RT) and hormonal therapy such as androgen deprivation therapy (ADT).</p><p class="headingAnchor" id="H21065940"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>It is well established that RT is associated with an increased risk of coronary [<a href="#rid10">10,11</a>] and carotid artery disease [<a href="#rid12">12-14</a>]. This is believed to be secondary to damage to the microvasculature, which results in endothelial dysfunction, inflammation, oxidative stress, and accelerated atherosclerosis.</p><p>The risk from RT has been well characterized in patients with breast cancer or lymphoma [<a href="#rid10">10</a>]. Historical data from breast cancer participants treated from 2005 to 2008 suggested that the incidence of adverse cardiovascular (CV) events was 3.3 percent over a median follow-up time of 7.6 years (range 0.1 to 10.1 years). Each gray (Gy) of radiation delivered to the heart was associated with a 16.5 percent increased risk of adverse events [<a href="#rid15">15</a>]. In childhood cancer survivors, the risk of cardiotoxicity from RT was shown to be dose dependent, with the cumulative incidence of symptomatic coronary artery disease (CAD) at age 50 years increasing to 20 percent in males exposed to &gt;35 Gy [<a href="#rid16">16</a>].</p><p>The adverse CV effects of RT are also becoming increasingly recognized in other malignancies, including non-small cell lung cancer where higher heart radiation doses have been associated with worse overall survival [<a href="#rid17">17,18</a>]. Moreover, any vascular location that is in the radiation field is at increased risk for early atherosclerosis. This is particularly relevant among patients with head and neck cancer because neck RT is a major risk factor for significant carotid disease [<a href="#rid19">19,20</a>], and the complexity of atherosclerosis can be quite challenging [<a href="#rid21">21</a>]. Further discussion on the cardiotoxicity, especially valvular disease, associated with RT is discussed separately. (See  <a class="medical medical_review" href="/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a>.)</p><p>There may be no symptoms attributable to either CAD or carotid disease in patients previously treated with RT. Therefore, clinicians should be proactive about age-appropriate CV risk factors and disease screening for potentially significant yet asymptomatic disease in these patients [<a href="#rid22">22-24</a>]. This includes periodic surveillance for cardiomyopathy by echocardiography in high-risk individuals and surveillance of coronary disease by noninvasive cardiac stress testing following RT and at least every five years. Moreover, invasive coronary angiography may be indicated to evaluate for CAD. For patients at risk for carotid artery disease, ultrasound is the safest and most effective screening tool. Other modalities may also be recommended depending upon patient characteristics and institutional expertise. (See  <a class="medical medical_review" href="/d/html/1519.html" rel="external">"Screening for coronary heart disease"</a>.)</p><p>Beyond screening, aggressive management of known cardiac risk factors is the best prevention for atherosclerosis in a cancer survivor. (See  <a class="medical medical_review" href="/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a>.)</p><p>These include the following [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Adequate blood pressure and glucose control (especially for patients with diabetes mellitus). (See  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Daily <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in select patients following a discussion of risks and benefits. (See  <a class="medical medical_review" href="/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Statin-based lipid-lowering therapy, with further risk stratification aided by coronary artery calcification assessment and atherosclerotic CV disease risk assessment. (See  <a class="medical medical_review" href="/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiplatelet therapy in selected patients. (See  <a class="medical medical_review" href="/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use"</a>.)</p><p></p><p>Regular exercise, tobacco cessation, and healthy dietary habits are also major components of effective management strategies. These are associated with improved survival in all patients, including those treated for cancer [<a href="#rid26">26-28</a>]. (See  <a class="medical medical_review" href="/d/html/14222.html" rel="external">"The roles of diet, physical activity, and body weight in cancer survivors"</a> and  <a class="medical medical_review" href="/d/html/1510.html" rel="external">"Exercise and fitness in the prevention of atherosclerotic cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H21065952"><span class="h3">Androgen deprivation therapy</span><span class="headingEndMark"> — </span>Androgen deprivation therapy (ADT) is used in the treatment of prostate cancer. ADT utilizes hormonal agents, such as gonadotropin-releasing hormone (GnRH) agonists (<a class="drug drug_general" data-topicid="9549" href="/d/drug information/9549.html" rel="external">leuprolide</a>, <a class="drug drug_general" data-topicid="8500" href="/d/drug information/8500.html" rel="external">goserelin</a>, <a class="drug drug_general" data-topicid="10018" href="/d/drug information/10018.html" rel="external">triptorelin</a>) and antagonists (<a class="drug drug_general" data-topicid="9073" href="/d/drug information/9073.html" rel="external">degarelix</a>, <a class="drug drug_general" data-topicid="130388" href="/d/drug information/130388.html" rel="external">relugolix</a>), as well as antiandrogens (<a class="drug drug_general" data-topicid="8471" href="/d/drug information/8471.html" rel="external">flutamide</a>, <a class="drug drug_general" data-topicid="9154" href="/d/drug information/9154.html" rel="external">bicalutamide</a>, <a class="drug drug_general" data-topicid="86370" href="/d/drug information/86370.html" rel="external">enzalutamide</a>). (See  <a class="medical medical_review" href="/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy"</a>.)</p><p>Although previous retrospective studies were inconsistent [<a href="#rid29">29-31</a>], prospective studies and randomized trials have demonstrated the risks of CAD or myocardial infarction (MI) associated with ADT [<a href="#rid32">32-34</a>]. These data suggest that CV adverse events (especially hypertension [HTN], ischemic heart disease, and MI) are frequently encountered safety concerns, and that optimal CV risk factor control and encouragement of regular exercise should be recommended.</p><p>We agree with the consensus statement from the American Heart Association (AHA), American Cancer Society, and the American Urologic Association that states patients receiving ADT should be evaluated annually with an examination of blood pressure, serum measurements of lipid profiles, and checks of fasting glucose levels. In addition, patients should undergo primary and secondary preventive measures [<a href="#rid35">35</a>]. Both aggressive cardiac risk factor modification and appropriate screening are the guiding principles of optimal care, and some have proposed an "ABCDE" algorithm addressing awareness and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> therapy, blood pressure, cholesterol and cigarette cessation, diet and diabetes, and exercise [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p>Several randomized trials have attempted to inform the question of optimal strategy for ADT and hormonal-based therapy for prostate cancer [<a href="#rid32">32-34</a>]. As an example, one randomized trial of patients with prostate cancer treated with GnRH agonist or antagonist for one year indicated that GnRH agonists resulted in higher rates of major CV and cerebrovascular events than GnRH antagonists [<a href="#rid37">37</a>]. Prolonged ADT is also highly associated with worsened cardiorespiratory fitness [<a href="#rid38">38</a>] and has negative effects on obesity with resultant worsening CV disease and all-cause mortality [<a href="#rid39">39</a>], visceral adiposity, insulin sensitivity, metabolic syndrome, and dyslipidemia [<a href="#rid40">40</a>].</p><p>Examples of the retrospective data on ADT and CV risk include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective analysis of the Surveillance, Epidemiology, and End-Results (SEER)-Medicare database examined 22,816 prostate cancer patients who had survived for one year after diagnosis. Patients who received ADT had a 20 percent increased incidence of CAD over a mean follow-up period of five years, compared with those who were not treated with ADT (hazard ratio [HR] 1.20, 95% CI 1.15-1.26) [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, a meta-analysis that included randomized trials with follow-up ranging from 7.6 to 13.2 years did not show an association between ADT and an increased risk of CV mortality [<a href="#rid31">31</a>].</p><p></p><p>However, potential concerns have been raised over these analyses, including:</p><p class="bulletIndent1"><span class="glyph">●</span>A lack of generalizability of clinical trial participants to the general population</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of competing risks</p><p class="bulletIndent1"><span class="glyph">●</span>The potential for outcomes misclassification, resulting in underreporting of CV deaths </p><p></p><p>Any of these may have resulted in an underestimation the CV risk among males using ADT. Moreover, data support that CV risk factors are underassessed and undertreated in males receiving ADT [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H30618814"><span class="h2">Childhood cancer survivors</span><span class="headingEndMark"> — </span>Childhood cancer survivors are at increased risk of cardiovascular disease [<a href="#rid16">16,42,43</a>]. On average, survivors of childhood cancer have a greater than 10-fold risk of ischemic heart disease and stroke compared with siblings [<a href="#rid8">8,44</a>]. This risk can persist for at least four decades after treatment completion [<a href="#rid5">5</a>]. </p><p>Cardiovascular disease is also a leading contributor to morbidity and mortality in survivors of childhood cancer [<a href="#rid44">44-51</a>]. In an observational study from the Childhood Cancer Survivor Study Cohort (CCSS) of 34,230 childhood cancer survivors, the 40-year cumulative all-cause mortality was 23 percent, over half of which were due to health-related causes [<a href="#rid51">51</a>]. Cancer survivors 40 years or more from diagnosis had 131 excess health-related deaths per 10,000-person years, with heart disease and cerebrovascular disease (absolute excess risk of 27 and 10 per 10,000-person years, respectively) among the most common causes. Cancer survivors were also at significantly increased risk of death due to heart disease (standardized mortality ratio [SMR] 4.3) and cerebrovascular disease (SMR 5.1) compared with the general population. Notably, healthy lifestyle and absence of hypertension and diabetes were associated with reduced health-related mortality. These data suggest the importance of long-term surveillance, recognition, and treatment of cardiovascular disease in childhood cancer survivors as they transition into adults. (See <a class="local">'Surveillance guidelines for cardiovascular disease'</a> below.)</p><p>Long-term follow-up studies in cohorts of childhood cancer survivors have led to the development of cardiac risk calculators as well as surveillance guidelines for cardiac disease [<a href="#rid52">52</a>]. These studies also support advances in cancer treatment that limit cardiotoxicity, such as RT techniques that reduce cardiac radiation exposure [<a href="#rid5">5,53</a>].</p><p class="headingAnchor" id="H3344963218"><span class="h3">Cardiac risk factor prediction model</span><span class="headingEndMark"> — </span>Cardiac risk factor prediction models are available that have been validated in cancer survivors [<a href="#rid43">43,54</a>]. As an example, one prediction model was developed based on the CCSS cohort that included sex; age at cancer diagnosis; use of alkylating agents, anthracyclines, and/or vinca alkaloids; and cranial, neck, chest, and abdominal RT. Risk scores were then summed to create low-, intermediate-, and high-risk groups for both outcomes. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fccss.stjude.org%2Ftools-documents%2Fcalculators-other-tools%2Fccss-cardiovascular-risk-calculator.html&amp;token=7DhSfZdL6BuUzLtkqp8t%2Forb%2BFJU8azr0PCgUGSe5fBe3KR96nre0ADheDpILQnEeKFyQEW%2B9526318symc63dep3oqDQHnkJB5dqv6ehwF4TajCiZ2VP56IcRHyn%2BLN&amp;TOPIC_ID=17017" target="_blank">CV risk calculator</a> for the prediction of heart failure (HF), ischemic heart disease, and stroke is available online.</p><p>This cardiac risk factor prediction model was based on a review of 13,060 participants in the Childhood Cancer Survivor Study (CCSS) who were diagnosed and treated for cancer prior to age 21 and were observed through the age of 50 [<a href="#rid43">43</a>]. Ischemic heart disease and stroke occurred in 265 (2 percent) and 295 (2.25 percent), respectively; the risk could be predicted based on clinical factors that were available at the end of treatment. The cumulative incidence of both ischemic heart disease and stroke at age 50 years among low-risk groups was &lt;5 percent, compared with approximately 20 percent for the high-risk groups. By contrast, the cumulative incidence was only 1 percent for controls not treated for a childhood cancer (siblings). </p><p class="headingAnchor" id="H1194883714"><span class="h3">Surveillance guidelines for cardiovascular disease</span><span class="headingEndMark"> — </span>Long-term follow-up guidelines are available from the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.survivorshipguidelines.org%2F&amp;token=S16MTPPY6cpS0A68kxrRsQOkLnEIm8%2BQaMhQyNKCcl%2BJTIC9BC9aNpypysLPfb9F&amp;TOPIC_ID=17017" target="_blank">Children's Oncology Group</a> for survivors of childhood, adolescent, and young adult cancer that include specific recommendations for CV monitoring after chemotherapy and RT. A specific recommendation to consider cardiology consultation 5 to 10 years after RT is made for individuals who received ≥35 Gy of chest irradiation, or ≥15 Gy chest irradiation plus an anthracycline, and for those who received ≥40 Gy of RT to the neck to consider a color Doppler examination of the carotids 10 years after completion of RT to the neck as a baseline.</p><p>Cancer survivors should also be screened for cardiovascular disease by reviewing available computed tomography (CT) chest imaging (eg, studies previously performed for cancer staging or surveillance) for calcifications in any coronary or vascular bed exposed to RT. For patients with such calcifications, a coronary artery calcium score (CAC) can be obtained to screen for high-risk coronary artery disease [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/5297.html" rel="external">"Coronary artery calcium scoring (CAC): Overview and clinical utilization"</a>.)</p><p>Surveillance guidelines for cardiomyopathy in childhood cancer survivors are discussed separately. (See <a class="local">'Surveillance guidelines for myocardial dysfunction'</a> below.)</p><p class="headingAnchor" id="H21065964"><span class="h1">HYPERTENSION</span></p><p class="headingAnchor" id="H3355982836"><span class="h2">Effect of cancer therapy on hypertension</span><span class="headingEndMark"> — </span>Hypertension (HTN) is a long-term consequence of many cancer therapies, including both chemotherapy and targeted agents.</p><p class="headingAnchor" id="H47350330"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>Alkylating and alkyl-like agents such as <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> are associated with HTN, with effects mediated by vascular endothelial injury and nephrotoxicity [<a href="#rid56">56</a>]. For example, cisplatin exerts cytotoxic effects via the formation of covalent adducts with DNA purine bases and inter- and intra-strand cross-links, which can persist in multiple organ systems and circulate for many years after exposure [<a href="#rid57">57-59</a>]. At the vascular level, cisplatin appears to abolish capillary beds [<a href="#rid60">60</a>]. Furthermore, animals treated with cisplatin demonstrate increased levels of TNF alpha and multiple cytokines [<a href="#rid61">61</a>] and markers of oxidative stress [<a href="#rid62">62</a>]. Although speculative, these factors may help to explain long-standing toxicities related to cisplatin, including HTN. </p><p>Among chemotherapeutic agents, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> has been associated with HTN, based on preclinical data and from the evaluation of males treated for testicular cancer [<a href="#rid63">63,64</a>]. Unfortunately, limited data exist in females treated with a platinum agent. Clinical data on cisplatin and HTN include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study in which these survivors were followed for a median duration of 11.2 years, major results included that [<a href="#rid63">63</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Survivors of testicular cancer had significant increases in age, testosterone, and body mass index-adjusted blood pressure, on the order of 2.3 mmHg for systolic and 1.8 mmHg for diastolic blood pressure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Compared with healthy controls, the risk of incident HTN was significantly elevated in testicular cancer survivors (odds ratio [OR] 1.4, 95% CI 1.2-1.7). Subgroup analyses demonstrated that the age-adjusted odds of HTN were greatest in the <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> treated group, particularly at dosages &gt;850 mg (OR 2.4, 95% CI 1.4-4).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of testicular cancer survivors who were followed for a median time of 19 years, males who had received chemotherapy (n = 364) had an increased prevalence of antihypertensive medication use compared with the general population (OR 3.7, 95% CI 1.9-5.2) [<a href="#rid64">64</a>].</p><p></p><p class="headingAnchor" id="H426934653"><span class="h3">Targeted therapy</span><span class="headingEndMark"> — </span>In addition to chemotherapeutic agents, inhibitors that target the vascular endothelial growth factor receptor (VEGFR) signaling pathways are highly associated with significant HTN, especially during active therapy [<a href="#rid65">65-69</a>]. Mechanistically, VEGFR inhibitor therapy causes HTN through increased vascular resistance mediated by a reduction in nitric oxide production and angiogenesis, in addition to impaired natriuresis, endothelin-1-mediated vasoconstriction, capillary rarefaction, and systemic thrombotic microangiopathy [<a href="#rid70">70</a>]. However, the long-term effects on blood pressure and the vasculature are unknown. (See  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Hypertension'</a>.)</p><p>Clinical data on VEGFR and tyrosine kinase inhibitors (TKIs) include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review and meta-analysis of 77 studies of angiogenesis inhibitors concluded that the OR for HTN was 5.28 (95% CI 4.53-6.15) with angiogenesis inhibitors compared with routine care with a number needed to harm of six. Additionally, the OR for severe HTN, defined as blood pressure ≥160/100 mmHg, was 5.59 (95% CI 4.67-6.69) with a number needed to harm of 17 [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 71 randomized controlled trials comprising over 29,000 patients concluded that the relative risk (RR) of HTN with TKI therapy was 3.78 (95% CI 3.15-4.54) [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective, single-center study of 228 patients with metastatic renal cell carcinoma treated with VEGFR TKIs demonstrated a significant increase in blood pressure relative to baseline. The use of calcium channel blockers and potassium-sparing diuretics significantly lowered blood pressure during therapy [<a href="#rid73">73</a>].</p><p></p><p class="headingAnchor" id="H3934300265"><span class="h2">Risks of hypertension in cancer survivors</span><span class="headingEndMark"> — </span>HTN and other common cardiovascular (CV) risk factors significantly promote the development of CV disease in cancer survivors. The prevalence of HTN in childhood cancer survivors is approximately 2.5 times higher than in noncancer survivors. Nevertheless, cancer survivors are at risk for undertreatment of HTN, along with other modifiable CV risk factors [<a href="#rid74">74</a>]. Active areas of investigation include the role of genetics, in addition to treatment-related risk factors, in identifying childhood cancer survivors at increased risk of developing HTN [<a href="#rid75">75</a>].</p><p>An analysis of 10,725 five-year survivors and 3159 siblings in the Childhood Cancer Survivor Study (CCSS) determined that two or more CV risk factors were reported in a greater number of survivors than siblings, and HTN increased the risk for coronary artery disease (CAD), heart failure (HF), valvular disease, and arrhythmia [<a href="#rid8">8</a>]. Moreover, the combined effect of chest radiation therapy (RT) and HTN, as well as anthracyclines and HTN, resulted in a more than additive increased risk of subsequent CV events  (<a class="graphic graphic_table graphicRef114737" href="/d/graphic/114737.html" rel="external">table 1</a>) [<a href="#rid8">8</a>].</p><p>HTN was furthermore associated with an increased risk of CV mortality in this population. In survivors of adult-onset cancers, findings have been similar [<a href="#rid76">76</a>]. Cancer survivors with CV risk factors have a higher risk of CV disease, and those who develop CV disease have worse survival  (<a class="graphic graphic_figure graphicRef114741" href="/d/graphic/114741.html" rel="external">figure 1</a>) [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H21065984"><span class="h2">Management recommendations for cancer therapy-induced hypertension</span><span class="headingEndMark"> — </span>The available medications to treat HTN are described in the Joint National Committee guidelines [<a href="#rid77">77</a>]. The American College of Cardiology/American Heart Association (ACC/AHA) HF guidelines also recommend blood pressure control as a major strategy to prevent overt HF. In addition, patients treated with cardiotoxic chemotherapy are considered to have stage A HF [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/d/html/131241.html" rel="external">"Asymptomatic left ventricular diastolic dysfunction", section on 'Definitions'</a>.)</p><p>For HTN screening and monitoring of treated HTN in patients with cancer therapy-related HTN, we follow established guidelines for the general population. (See  <a class="medical medical_review" href="/d/html/3879.html" rel="external">"Blood pressure measurement in the diagnosis and management of hypertension in adults"</a> and  <a class="medical medical_review" href="/d/html/3820.html" rel="external">"Out-of-office blood pressure measurement: Ambulatory and self-measured blood pressure monitoring"</a>.)</p><p>Specific approaches for managing HTN induced by cancer therapy are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess for modifiable drivers of hypertension </strong>– In all patients with cancer therapy-related HTN, especially for those with HTN refractory to multiple agents, it is important to address modifiable drivers of elevated blood pressure, such as cancer-related pain. In patients with refractory HTN receiving cancer therapy, it may be reasonable to consider dose reduction or temporary discontinuation of chemotherapeutic agents or other medications that may contribute to HTN, in consultation with the patient's oncologist. Examples include nonsteroidal antiinflammatory drugs, high-dose corticosteroids, and erythropoietin-stimulating agents [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>White coat and masked hypertension </strong>– White coat HTN (elevated office-based blood pressure with normal out-of-office blood pressure) and masked HTN (normal office-based blood pressure with elevated out-of-office blood pressure) are both associated with increased risk of adverse CV outcomes and transition to sustained HTN. White coat HTN may be more common in patients receiving cancer treatment compared with the general population, due to increased anxiety surrounding cancer diagnosis and prognosis. In addition, masked HTN may also be more common in patients receiving cancer therapy, potentially due to delayed cancer therapy-induced HTN [<a href="#rid70">70</a>]. This makes out-of-office ambulatory blood pressure monitoring especially important in this patient population. (See  <a class="medical medical_review" href="/d/html/123119.html" rel="external">"White coat and masked hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lifestyle measures </strong>– Management of HTN typically consists of lifestyle measures including counseling on a low-sodium diet and exercise in all patients. (See  <a class="medical medical_review" href="/d/html/3878.html" rel="external">"Diet in the treatment and prevention of hypertension"</a> and  <a class="medical medical_review" href="/d/html/3828.html" rel="external">"Exercise in the treatment and prevention of hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of antihypertensive agent(s) </strong>– The initial choice of antihypertensive agents for cancer therapy-mediated HTN often includes renin-angiotensin system blockers (eg, angiotensin-converting enzyme [ACE] inhibitors or angiotensin II receptor blockers [ARB]) and beta blockers (BB), as these agents prevent adverse cardiac remodeling. Since HTN may result from nephrotoxicity following cancer treatment, we assess for proteinuria (spot protein to creatinine ratio of ≥500 mg/g or albuminuria to creatinine ratio of ≥300 mg/g). If proteinuria is present, we suggest preferentially initiating or titrating an ACE inhibitor or ARB [<a href="#rid70">70</a>]. Once the maximum tolerated dose of a single agent has been attained, additional first-line antihypertensive medications may be added for blood pressure control as necessary.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other available agents for cancer therapy-related HTN include mineralocorticoid antagonists and diuretics. If patients are being evaluated for these therapies, it is important to account for the risk of volume depletion and electrolyte abnormalities in patients likely to experience adverse effects from cancer therapies including reduced oral intake and gastrointestinal losses. (See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Calcium channel blockers are also an option. Depending upon the mechanism of HTN (ie, impact on arterial stiffness, pulsatile or resistive load), particularly with VEGFR inhibitors, medications with a primary vasodilator effect may be more effective at controlling blood pressure. However, we typically avoid non-dihydropyridine calcium channel blockers (<a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>). These agents inhibit cytochrome P450 3A4  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 2</a>), a family of enzymes involved in the metabolism of many chemotherapeutic agents, and their use may worsen chemotherapy-related toxicity [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/d/html/3832.html" rel="external">"Major side effects and safety of calcium channel blockers", section on 'Types of calcium channel blockers'</a>.)</p><p></p><p class="headingAnchor" id="H21065990"><span class="h1">HYPERLIPIDEMIA</span></p><p class="headingAnchor" id="H589126255"><span class="h2">Effect of cancer therapy on hyperlipidemia</span><span class="headingEndMark"> — </span>Treatments for cancer may increase lipid levels among cancer survivors. Examples of this include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with breast cancer on aromatase inhibitors </strong>– Aromatase inhibitors (AIs) block the conversion of androgens to estrogen and have variable effects on lipids [<a href="#rid79">79-81</a>]. An analysis of pooled data from seven clinical trials (n = 30,023 patients) demonstrated that longer duration of AI use was associated with a statistically significant increase in the odds of hypercholesterolemia as compared with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> [<a href="#rid79">79</a>]. </p><p></p><p class="bulletIndent1">In addition, there may be a slight difference on lipid profiles between the different AIs. Four-year follow-up of participants in one randomized trial reported that patients who took <a class="drug drug_general" data-topicid="8780" href="/d/drug information/8780.html" rel="external">anastrozole</a> had a slightly higher incidence of hypertriglyceridemia (3 versus 2 percent, respectively) and hypercholesterolemia (18 versus 15 percent) compared with those who took <a class="drug drug_general" data-topicid="8920" href="/d/drug information/8920.html" rel="external">exemestane</a> [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer", section on 'Comparison between AIs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients after allogeneic hematopoietic stem cell transplantation</strong> – In a retrospective study of 761 patients who underwent transplant at a single institution from 1998 to 2008 and survived at least 100 days, 73.4 percent developed hypercholesterolemia and 72.5 percent developed hypertriglyceridemia in the first two years. Acute graft-versus-host disease (GVHD) was independently associated with hypercholesterolemia and hypertriglyceridemia [<a href="#rid82">82</a>]. A retrospective study of 194 transplant patients at another institution from 1995 to 2008 revealed 42.8 percent developed hypercholesterolemia and 50.8 percent hypertriglyceridemia. Similarly, chronic GVHD and steroid use were independently associated with hypercholesterolemia [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Survivors of testicular cancer treated with radiation therapy (RT) and/or chemotherapy</strong> – There is an increased incidence of hyperlipidemia among males treated for testicular cancer, which appears to be associated with RT and/or chemotherapy. (See  <a class="medical medical_review" href="/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors", section on 'Hyperlipidemia'</a>.)</p><p></p><p class="bulletIndent1">In one study, testicular cancer survivors previously treated with RT and chemotherapy had significantly lower levels of high-density lipoprotein (HDL) compared with patients treated with surgery only [<a href="#rid64">64</a>]. Testicular cancer survivors had an increased odds of being on lipid-lowering medication compared with normal controls (odds ratio [OR] between 1.8 and 2.6), regardless of treatment type at diagnosis (surgery, RT, chemotherapy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Survivors of prostate cancer treated with ADT</strong> – Males treated with ADT for prostate cancer can experience persistent changes in their body composition, including decreases in lean body mass, increases in fat mass [<a href="#rid84">84</a>], and alterations in insulin sensitivity [<a href="#rid85">85</a>]. For example, in one study of patients who had received ADT for 12 months, significant increases in total cholesterol, low-density lipoprotein, and non-HDL were noted [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy", section on 'Potential cardiovascular harm'</a>.)</p><p></p><p class="headingAnchor" id="H1245640"><span class="h2">Management guidelines</span><span class="headingEndMark"> — </span>For patients with hyperlipidemia as a result of cancer-related treatment, the current accepted standards are to use lipid-lowering guidelines, which are described separately. (See  <a class="medical medical_review" href="/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.) </p><p class="headingAnchor" id="H21065996"><span class="h1">CARDIAC STRUCTURAL COMPLICATIONS</span></p><p class="headingAnchor" id="H3420578020"><span class="h2">Effect of cancer therapy on cardiac structure</span><span class="headingEndMark"> — </span>Cancer therapy can potentially result in damage to multiple cardiac structures as a late complication. However, this may not be manifest for years after treatment has completed [<a href="#rid86">86</a>]. For patients who experience issues related to structural damage to the heart, close monitoring is essential [<a href="#rid87">87</a>]. In addition, a medical evaluation is necessary to determine if other causes of cardiac dysfunction are present.</p><p>Close monitoring is important because the timing of surgical or medical treatment can be critical for optimal outcomes. The American Society of Oncology has led an effort in publishing a clinical practice guideline in the "Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers." Briefly, this review and expert consensus statement summarized key recommendations for cardiac monitoring and treatment of dysfunction and also provided the definition of risk factors for cardiac dysfunction, components of comprehensive cardiovascular (CV) assessment, various strategies for minimizing cardiac risk during treatment, and monitoring strategies during and after cancer therapy  (<a class="graphic graphic_table graphicRef116340" href="/d/graphic/116340.html" rel="external">table 3</a>) [<a href="#rid88">88</a>]. The European Society of Cardiology has also provided a position paper on cancer treatments focused on a comprehensive overview of cardiotoxicities with cancer therapies before, during, and after treatment [<a href="#rid89">89</a>]. The European Society of Medical Oncology also provided a consensus document for the management of CV disease throughout the spectrum of cancer treatment [<a href="#rid90">90</a>].</p><p>The impact of prior cancer treatment has been well illustrated in adult survivors of childhood cancers. Compared with siblings, adult survivors of childhood cancers have an increased age-adjusted rate of valvular abnormalities, pericardial disease, and heart failure (HF) over a time from of 7 to 50 years [<a href="#rid91">91</a>]. In a study of 1853 adult survivors of childhood cancers, cardiomyopathy was detected in 7.4 percent of survivors, coronary artery disease (CAD) in 3.8 percent, valvular regurgitation or stenosis in 28 percent, and conduction abnormalities in 4.4 percent. Nearly all were asymptomatic and the prevalence of abnormalities increased with age, and were associated with anthracycline dose and radiation exposure [<a href="#rid45">45</a>]. Similarly, additional data suggest that cancer survivors may have an increased prevalence of both overt and subclinical abnormalities in cardiac function, in sensitive measures of cardiac mechanics [<a href="#rid92">92</a>]. In a study of 1820 adult survivors of childhood cancers from the same group, abnormal global longitudinal strain existed in 28 percent of patients and was associated with prior exposure to chest radiation therapy (RT), anthracycline dose, and metabolic syndrome. Abnormalities in circumferential strain have also been noted with anthracycline and/or <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> exposure in adult breast cancer patients [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H86926679"><span class="h2">Valvular degeneration and calcification</span><span class="headingEndMark"> — </span>Valvular issues resulting in stenosis and/or regurgitation are established long-term consequences of mediastinal radiation [<a href="#rid94">94-96</a>]. (See  <a class="medical medical_review" href="/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a>.)</p><p>For patients in whom a valvular condition has been detected, the American College of Cardiology/American Heart Association (ACC/AHA) guidelines for valvular heart disease can be used to help direct care. (See  <a class="medical medical_review" href="/d/html/8164.html" rel="external">"Clinical manifestations and diagnosis of aortic stenosis in adults"</a> and  <a class="medical medical_review" href="/d/html/8173.html" rel="external">"Rheumatic mitral stenosis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation"</a> and  <a class="medical medical_review" href="/d/html/8159.html" rel="external">"Clinical manifestations and diagnosis of chronic aortic regurgitation in adults"</a>.)</p><p>Echocardiography is an essential tool that is used to define disease severity and progression of valvular heart disease, and can be applied in accordance with accepted guidelines and standards [<a href="#rid78">78,97,98</a>]. If structural disease is suspected but the noninvasive work-up is not conclusive, right heart catheterization can also be performed to assess hemodynamics, particularly when intervention is being considered. </p><p>The impact of mediastinal radiation on valvular disease is illustrated by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional study of over 1800 adult survivors of childhood cancer who had received cardiotoxic anticancer treatments at least a decade earlier, valvular regurgitation or stenosis was present in 28 percent [<a href="#rid45">45</a>]. Radiation exposure exceeding 1500 centigray (cGy) resulted in the greatest risk for developing valvular disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 415 survivors of Hodgkin lymphoma who received mediastinal irradiation, with a minimum of two years of follow-up, 6.2 percent developed clinically significant valvular disease at a median of 22 years [<a href="#rid94">94</a>]. Patients who developed valvular damage had received higher doses of radiation (37 gray [Gy; 23 to 44 Gy] versus 33 Gy [10 to 47 Gy]). The most common valvular abnormality was aortic stenosis followed by (in order of decreasing frequency) mitral regurgitation, mitral stenosis, tricuspid regurgitation, and aortic regurgitation. These findings have been corroborated by other investigators, including a study of 1279 survivors of Hodgkin lymphoma that demonstrated a cumulative incidence of moderate to severe valvular disease of 0.5 percent at five years that increased to 8.7 percent at 25 years of follow-up, and typically occurred at a median of 15 years after RT [<a href="#rid99">99</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional study of 82 survivors of Hodgkin lymphoma, severe valvular disease was seen more frequently in those that received mediastinal radiation compared with those who did not (24.5 versus 3.4 percent). The most common valvular abnormality was aortic regurgitation [<a href="#rid100">100</a>].</p><p></p><p class="headingAnchor" id="H86926685"><span class="h2">Pericardial disease</span><span class="headingEndMark"> — </span>Pericardial disease, usually manifest as pericardial effusion with or without tamponade, or pericardial constriction may be particularly difficult clinical conditions encountered in cancer survivors [<a href="#rid101">101</a>]. Although pericardial effusions are typically seen in the active treatment phase of solid tumors, this can be as a late consequence of chest RT, although it is uncommon [<a href="#rid102">102</a>]. In many instances, a pericardial effusion or constriction can be observed for an extended period of time, and symptoms due to HF may occur late. (See  <a class="medical medical_review" href="/d/html/111731.html" rel="external">"Cardiotoxicity of radiation therapy for Hodgkin lymphoma and pediatric malignancies", section on 'Pericarditis'</a>.)</p><p>For patients in whom pericardial disease is suspected, monitoring is best done by echocardiography and periodic clinical assessment [<a href="#rid103">103,104</a>]. (See  <a class="medical medical_review" href="/d/html/5299.html" rel="external">"Echocardiographic evaluation of the pericardium"</a>.)</p><p class="headingAnchor" id="H86926691"><span class="h2">Conduction disease</span><span class="headingEndMark"> — </span>Dysfunction of cardiac conduction is indicative of structural damage. Sick sinus syndrome, bradycardia, and heart block have been reported among patients treated for lymphoma, especially following treatment with mediastinal or chest wall RT [<a href="#rid99">99,105</a>]. In addition, there are reports of persistent tachycardia and loss of circadian variability in heart rate. (See  <a class="medical medical_review" href="/d/html/111731.html" rel="external">"Cardiotoxicity of radiation therapy for Hodgkin lymphoma and pediatric malignancies", section on 'Arrhythmias'</a>.)</p><p>For patients who received chest wall RT, surveillance is suggested. If asymptomatic, this can be done with a routine electrocardiogram (ECG). For symptomatic patients (eg, lightheadedness, syncope, or palpitations), noninvasive or electrophysiologic studies may be required, especially if the ECG is nondiagnostic. (See  <a class="medical medical_review" href="/d/html/961.html" rel="external">"Arrhythmia management for the primary care clinician"</a> and  <a class="medical medical_review" href="/d/html/1072.html" rel="external">"Sinus node dysfunction: Treatment"</a>.)</p><p class="headingAnchor" id="H21066008"><span class="h1">MYOCARDIAL DYSFUNCTION, CARDIOMYOPATHY, AND HEART FAILURE</span></p><p class="headingAnchor" id="H3449647266"><span class="h2">Cancer populations at risk for cardiomyopathy</span><span class="headingEndMark"> — </span>Cancer survivors are at higher risk of myocardial (cardiac) dysfunction, cardiomyopathy, and heart failure (HF) compared with populations without cancer [<a href="#rid3">3,106-108</a>]. These conditions are typically late effects of cancer therapy from both solid and hematologic malignancies [<a href="#rid3">3</a>]. Cancer survivors who develop cardiomyopathy or HF are at risk for significant morbidity and mortality [<a href="#rid46">46,109,110</a>]. Therefore, it is important to detect cardiac dysfunction early and provide cardiac-specific therapy to prevent progression [<a href="#rid111">111,112</a>]. </p><p>The American College of Cardiology and American Heart Association (ACC/AHA) classify patients who have received cardiotoxic chemotherapy as having stage A HF [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/d/html/131241.html" rel="external">"Asymptomatic left ventricular diastolic dysfunction", section on 'Definitions'</a>.)</p><p>Moreover, the American Society of Clinical Oncology classifies specific patients as higher risk for developing cardiac dysfunction  (<a class="graphic graphic_table graphicRef116340" href="/d/graphic/116340.html" rel="external">table 3</a>). These include patients receiving high-dose cardiotoxic chemotherapy; RT to a field that includes the heart; combination cardiotoxic chemotherapy and chest RT; age &gt;60 years at time of treatment; and those with cardiac risk factors or existing cardiac history [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/d/html/111731.html" rel="external">"Cardiotoxicity of radiation therapy for Hodgkin lymphoma and pediatric malignancies", section on 'Heart failure'</a> and  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p class="headingAnchor" id="H2930997451"><span class="h2">Effect of cancer therapy on cardiomyopathy</span></p><p class="headingAnchor" id="H281625486"><span class="h3">Anthracyclines</span><span class="headingEndMark"> — </span>The chemotherapeutic agents most commonly associated with cardiotoxicity are the anthracycline analogues (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a>, <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>, as well as others  (<a class="graphic graphic_table graphicRef109645" href="/d/graphic/109645.html" rel="external">table 4</a>)). In adult cancer survivors, anthracyclines are associated with both systolic and diastolic dysfunction [<a href="#rid53">53,113-115</a>]. In childhood cancer survivors, anthracyclines can lead to congestive HF, one of the most common late cardiac effects in this population [<a href="#rid115">115</a>]. (See <a class="local">'Childhood cancer survivors'</a> below.)</p><p>Data suggest that cardiotoxicity may occur in the first one to two years post-anthracycline exposure [<a href="#rid93">93,116</a>].</p><p>The risk of cardiotoxicity differs by the type of anthracycline administered. For example, in one study of 28,423 childhood cancer survivors, relative to <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> was associated with decreased cardiomyopathy risk [<a href="#rid117">117</a>]. Of note, <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a> is considered 10 times more cardiotoxic than doxorubicin. Additionally, while mitoxantrone has traditionally been classified as an anthracycline, it may in fact result in cardiotoxicity through a distinct mechanism where it exhibits a nonlinear dose-response relationship with HF risk [<a href="#rid115">115</a>].</p><p>The total dose of anthracycline received is an important risk factor for long-term, subsequent cardiac dysfunction. The typical belief is that large doses (&gt;450 mg/m<sup>2 </sup>of <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>) induce cardiotoxicity [<a href="#rid45">45,91</a>]. For example, in one study, the frequency of doxorubicin-related HF was estimated to be 5 percent at a cumulative dose of 400 mg/m<sup>2</sup>, increasing to 26 percent at 500 mg/m<sup>2</sup> and 48 percent at 700 mg/m<sup>2 </sup>[<a href="#rid118">118</a>]. (See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity", section on 'Cumulative dose'</a>.)</p><p>However, patients can be susceptible to cardiomyopathy at lower doses. For example, detailed echocardiographic data from adult patients with breast cancer suggest that with anthracyclines (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> 240 mg/m<sup>2</sup>), there are modest but persistent declines in left ventricular ejection fraction (LVEF; approximately 4 percent) [<a href="#rid93">93</a>], as well as persistent worsening in diastolic function [<a href="#rid119">119</a>].</p><p>Genetic variation also contributes significantly to chemotherapy-related cardiotoxicity and can modify the relationship between anthracycline dose and cardiotoxicity risk. Data suggest a genetic basis for anthracycline-mediated cardiac dysfunction across multiple patient populations, including those with childhood cancer, survivors of childhood cancer [<a href="#rid120">120-122</a>], adult-onset cancer, and across the age spectrum [<a href="#rid123">123,124</a>]. Further details on pathogenic variants associated with anthracycline-induced cardiotoxicity are discussed separately. (See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity", section on 'Other factors'</a> and  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a>.)</p><p class="headingAnchor" id="H2615318987"><span class="h3">Other therapies</span><span class="headingEndMark"> — </span>Other cancer-related therapies associated with cardiac dysfunction include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trastuzumab</strong><strong> and other human epidermal growth factor receptor 2 (HER-2) targeted agents </strong>– <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">Trastuzumab</a> is a humanized monoclonal antibody targeting the ErbB2 receptor and is routinely administered in selected patients with breast cancer overexpressing HER2. Treatment with trastuzumab is associated with a risk of cardiac toxicity that is mechanistically distinct from that caused by anthracyclines. Trastuzumab-related cardiotoxicity is typically manifested by an asymptomatic decrease in the LVEF and is less commonly manifested by clinical HF. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/774.html" rel="external">"Cardiotoxicity of trastuzumab and other HER2-targeted agents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy</strong> – Patients with RT exposure to myocardial tissues are at increased risk of HF with preserved ejection fraction and restrictive cardiomyopathy. (See  <a class="medical medical_review" href="/d/html/3457.html" rel="external">"Pathophysiology of heart failure with preserved ejection fraction", section on 'Myocardial ischemia'</a> and  <a class="medical medical_review" href="/d/html/4918.html" rel="external">"Restrictive cardiomyopathies", section on 'Etiology'</a>.)</p><p></p><p class="bulletIndent1">Further details on the cardiotoxicities of RT in patient with cancer are discussed separately. (See  <a class="medical medical_review" href="/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a>.)</p><p></p><p class="bulletIndent1">RT and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> may induce synergistic cardiotoxic effects with each other and with other chemotherapeutic agents, resulting in subsequent cardiac toxicity in cancer survivors [<a href="#rid125">125</a>]. (See  <a class="medical medical_review" href="/d/html/111731.html" rel="external">"Cardiotoxicity of radiation therapy for Hodgkin lymphoma and pediatric malignancies", section on 'Incidence of cardiovascular disease'</a> and  <a class="medical medical_review" href="/d/html/14232.html" rel="external">"Approach to the adult survivor of classic Hodgkin lymphoma", section on 'Cardiovascular disease'</a> and  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity", section on 'Combined treatment with other cancer therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematopoietic cell transplantation (HCT)</strong> – Survivors of HCT have a higher incidence of CV disease when compared with their nontransplant siblings. (See  <a class="medical medical_review" href="/d/html/14228.html" rel="external">"Long-term care of the adult hematopoietic cell transplantation survivor", section on 'Cardiovascular'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiangiogenic agents</strong> – The natural history of cardiomyopathy secondary to antiangiogenic-based cancer therapy is still unclear, with few long-term data describing the outcomes. Some subsequent data suggest that in the short-term, declines in LVEF occur early and are manageable with close CV monitoring and follow-up [<a href="#rid126">126</a>]. (See  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Left ventricular dysfunction and myocardial ischemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune checkpoint inhibitors</strong> – Immune checkpoint inhibitors, or immunotherapy, can be associated with cardiovascular toxicity, including myocarditis and HF. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Cardiovascular toxicity'</a>.)</p><p></p><p class="headingAnchor" id="H3320902337"><span class="h2">Childhood cancer survivors</span><span class="headingEndMark"> — </span>Childhood cancer survivors are at increased risk for CV risk factors (eg, HTN) as well as CV disease (eg, cardiomyopathy and HF). Compared with siblings and the general population, the risk ratios range from 5 to 15 [<a href="#rid8">8,44,47,127</a>]. In pediatric-age childhood cancer survivors, one retrospective case-control study suggests that early longitudinal changes in functional and structural parameters on echocardiography are associated with the subsequent development of cardiomyopathy [<a href="#rid128">128</a>].</p><p>Risk of HF among treated childhood cancer survivors remains for at least four decades after completion of therapy, with the youngest children at diagnosis exhibiting the most vulnerability to long-term treatment-related cardiotoxicity [<a href="#rid5">5,129</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The specific risk was addressed in a review of over 13,000 participants in the Childhood Cancer Survivor Study (CCSS) who were diagnosed and treated for cancer prior to age 21 years and were observed through age 40 years [<a href="#rid130">130</a>]. HF occurred in 285 (2.2 percent), with a subsequent CCSS study suggesting an incidence of being waitlisted for or undergoing cardiac transplantation of approximately 0.5 percent after at least 35 years following initial cancer diagnosis [<a href="#rid131">131</a>]; the risk could be predicted based on factors that were available at the end of treatment, including cumulative anthracycline exposure and cardiac RT dose. (See <a class="local">'Heart failure risk calculator'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent analysis of an expanded CCSS cohort of 24,214 participants followed for up to 39 years demonstrated a dose-response relationship between anthracycline chemotherapy and HF, with children &lt;13 years of age at highest risk for HF [<a href="#rid5">5</a>]. Young children (&lt;4 years) exposed to low and intermediate lifetime cumulative anthracycline-based chemotherapy (&lt;250 mg/m<sup>2</sup>) had a twofold increased risk of HF relative to older children (&gt;13 years). This risk increased fourfold with higher cumulative anthracycline-based chemotherapy (≥250 mg/m<sup>2</sup>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar results were seen in another study of nearly 6000 childhood cancer survivors. In this study, approximately 40 years after diagnosis, the cumulative incidence of developing HF was 11 percent among those who received cardiotoxic chemotherapy and 29 percent among those who received both cardiotoxic chemotherapy and radiotherapy involving the heart [<a href="#rid115">115</a>].</p><p></p><p class="headingAnchor" id="H515585932"><span class="h3">Heart failure risk calculator</span><span class="headingEndMark"> — </span>A prediction model for HF risk was developed based on the CCSS cohort that included sex; age at cancer diagnosis; use of alkylating agents, anthracyclines, and/or vinca alkaloids; and cranial, neck, chest, and abdominal RT [<a href="#rid130">130</a>]. Risk scores were then summed to create low-, intermediate-, and high-risk groups. The cumulative incidences of HF at age 40 years among low-, intermediate-, and high-risk groups were 0.5, 2.4, and 11.7 percent, respectively; cumulative incidence was 0.3 percent for controls not treated for a childhood cancer (siblings). An <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fccss.stjude.org%2Ftools-documents%2Fcalculators-other-tools%2Fccss-cardiovascular-risk-calculator.html&amp;token=7DhSfZdL6BuUzLtkqp8t%2Forb%2BFJU8azr0PCgUGSe5fBe3KR96nre0ADheDpILQnEeKFyQEW%2B9526318symc63dep3oqDQHnkJB5dqv6ehwF4TajCiZ2VP56IcRHyn%2BLN&amp;TOPIC_ID=17017" target="_blank">online calculator</a> to estimate the risk of HF is available.</p><p>The addition of surveillance LVEF to a clinical risk score may also improve the prediction of LVEF &lt;40 percent, although further validation data are necessary [<a href="#rid113">113</a>]. In one study of 299 childhood cancer survivors, the addition of surveillance LVEF to a clinical risk score improved the 10-year prediction for subsequent development of LVEF &lt;40 percent [<a href="#rid113">113</a>]. More specifically, a mid-range LVEF 40 to 49 percent on initial surveillance echocardiogram increased the risk of developing LVEF &lt;40 percent by approximately eightfold relative to those with preserved LVEF &gt;50 percent. (See  <a class="medical medical_review" href="/d/html/117708.html" rel="external">"Treatment and prognosis of heart failure with mildly reduced ejection fraction"</a>.)</p><p class="headingAnchor" id="H964781199"><span class="h3">Surveillance guidelines for myocardial dysfunction</span><span class="headingEndMark"> — </span>Long-term follow-up guidelines are available from the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.survivorshipguidelines.org%2F&amp;token=S16MTPPY6cpS0A68kxrRsQOkLnEIm8%2BQaMhQyNKCcl%2BJTIC9BC9aNpypysLPfb9F&amp;TOPIC_ID=17017" target="_blank">Children's Oncology Group</a> for survivors of childhood, adolescent, and young adult cancer that include specific recommendations for CV monitoring after chemotherapy and RT. In addition, the International Late Effects of Childhood Cancer Guideline Harmonization Group has published recommendations regarding cardiomyopathy surveillance in childhood cancer survivors [<a href="#rid132">132,133</a>].</p><p class="headingAnchor" id="H3729320415"><span class="h2">Prevention of cardiac dysfunction and heart failure</span><span class="headingEndMark"> — </span>In patients receiving anthracyclines, various cardioprotective measures may be used to prevent long-term cardiac dysfunction such as <a class="drug drug_general" data-topicid="9338" href="/d/drug information/9338.html" rel="external">dexrazoxane</a> [<a href="#rid134">134,135</a>], liposomal anthracyclines, or infusional rather than bolus dosing of anthracyclines. Some studies have demonstrated improvement in survival with these strategies, although longer follow-up data are needed [<a href="#rid16">16</a>]. These preventative measures are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity", section on 'Primary prevention with cardiovascular drugs'</a>.)</p><p>In addition, among cancer patients receiving chemotherapy, prophylactic neurohormonal therapies including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, beta blockers, and mineralocorticoid receptor antagonists have been associated with an attenuation of LVEF declines on the order of 3.96 percent. However, in one meta-analysis, the absolute changes in LVEF were small, and significant heterogeneity across studies was observed for the prophylactic efficacy of neurohormonal therapies on chemotherapy-related cardiotoxicity [<a href="#rid136">136</a>]. Further prospective studies and randomized clinical trials of prophylactic cardioprotective strategies in cancer patients are necessary [<a href="#rid137">137</a>]. (See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity", section on 'Approaches to cardiotoxicity mitigation'</a>.)</p><p class="headingAnchor" id="H21066014"><span class="h2">Management of cardiac dysfunction and heart failure</span><span class="headingEndMark"> — </span>While cardiotoxicity related to anthracyclines was previously thought to be completely irreversible [<a href="#rid138">138</a>], contemporary data suggest that early identification of cardiotoxicity and prompt therapy for HF can lead to substantial improvement in LVEF to even normal levels [<a href="#rid139">139,140</a>]. One study suggested that, if subclinical left ventricular dysfunction is left untreated for six months or longer, there may be a lower likelihood of recovery [<a href="#rid140">140</a>]. In a follow-up study by this same group, LVEF assessment in cancer patients exposed to anthracyclines suggested that the incidence of cardiotoxicity, as defined by a decline in LVEF of &gt;10 percent to &lt;50 percent, occurred in 9 percent of patients with the majority occurring the first year after the completion of chemotherapy. A nontrivial proportion of patients did demonstrate recovery of LVEF to varying degrees [<a href="#rid116">116</a>].</p><p>With this principle in mind, cardiac biomarkers such as troponin I, B-type natriuretic peptide (BNP), and n-terminal proBNP (NT-proBNP) have shown some potential utility in the early detection of cardiotoxicity [<a href="#rid141">141</a>]. In addition, the optimization of cardioprotective medications may help prevent or ameliorate damage that may occur during cancer treatment [<a href="#rid142">142,143</a>]. This proactive process can potentially eliminate cardiotoxicity as a substantial late cardiac effect for cancer survivors, although studies are needed to be validated their use in this population [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a> and  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity", section on 'Preventive management of anthracycline therapy'</a> and  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity", section on 'Approaches to cardiotoxicity mitigation'</a>.)</p><p>Cardiac dysfunction related to therapy can recover when treated optimally with appropriate, guideline-directed medications for HF, including neurohormonal antagonists, beta blockers (BB), or diuretics when appropriate [<a href="#rid144">144</a>]. However, it is not always reversible, and useful clinical factors to predict the risk of serious HF have not been elucidated [<a href="#rid145">145</a>].</p><p>In the absence of data, it would be prudent to exercise extreme caution when withdrawing ACE-I or BB in patients with a history of transient treatment-related HF and/or left ventricular dysfunction. We advise only doing so potentially after a long period of stability has passed and provided the patient is no longer being actively treated for cancer.</p><p>For patients undergoing antiangiogenic therapy, appropriate cardiac risk factor management is imperative for optimal outcomes. This includes utilizing antihypertensive therapies that control blood pressure (eg, dihydropyridine calcium channel blockers such as <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a>) and prevent adverse cardiac remodeling (eg, ACE-I, ARB, or BB). Other important management principles potentially include <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, statin therapy, dietary sodium restriction, regular exercise, and weight control if possible. (See <a class="local">'Management recommendations for cancer therapy-induced hypertension'</a> above and  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a>.)</p><p class="headingAnchor" id="H369842690"><span class="h1">PULMONARY TOXICITY</span><span class="headingEndMark"> — </span>Cancer survivors are at increased risk for pulmonary disease that results from treatment with chemotherapy and radiation therapy (RT). These are reviewed below.</p><p class="headingAnchor" id="H369842701"><span class="h2">Pneumonitis</span><span class="headingEndMark"> — </span>Several chemotherapeutic agents are associated with interstitial pneumonitis, including <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a>, and <a class="drug drug_general" data-topicid="9206" href="/d/drug information/9206.html" rel="external">carmustine</a>. There also appears to be an increased incidence of pneumonitis with checkpoint inhibitors, the long-term consequences of which are unclear [<a href="#rid146">146</a>]. Pneumonitis has been also reported with other agents, such as those targeting the mTOR pathway [<a href="#rid147">147</a>]. Of these, the pulmonary complications associated with bleomycin (an agent commonly used to treat Hodgkin lymphoma and testicular cancer) have been best characterized.</p><p>While this drug can cause a variety of insults, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> interstitial pneumonitis (BIP) is the most common. Depending on the definition used, BIP has been reported to occur in up to 46 percent of patients [<a href="#rid148">148</a>]. BIP is of particular relevance to the long-term care of cancer survivors, given its potential progression to pulmonary fibrosis and associated increased mortality. For example, a study of 38,907 survivors of testicular cancer treated with bleomycin in the past revealed an increased standardized mortality ratio of 2.53 (95% CI 1.26-4.53) for respiratory diseases alone [<a href="#rid149">149</a>]. Late onset BIP typically develops more than six months after treatment [<a href="#rid150">150,151</a>], presenting as a nonproductive cough, dyspnea, tachypnea, fever, and cyanosis. Radiographic imaging demonstrates variable findings but can show bilateral bibasilar infiltrates [<a href="#rid148">148</a>]. Patients with BIP tend to respond to corticosteroids [<a href="#rid150">150,152</a>]. (See  <a class="medical medical_review" href="/d/html/4316.html" rel="external">"Bleomycin-induced lung injury"</a>.)</p><p>Pneumonitis can also occur with RT and typically occurs at least one to three months after completion of RT for lung, breast, esophageal cancers and bone metastases, Hodgkin and non-Hodgkin lymphoma, or total body irradiation for leukemia. The incidence and extent of radiation damage depends on the volume of lung irradiated, total radiation dose, and radiation fractions [<a href="#rid153">153</a>]. Again, common symptoms include dyspnea, hypoxia, nonproductive cough, and fever. Radiographic imaging tends to show changes confined to the outlines of radiation fields [<a href="#rid153">153</a>]. Steroids can be helpful and patients can have complete resolution of symptoms after six to eight weeks of treatment. Like BIP, however, radiation pneumonitis can progress to fibrosis, making this particularly relevant to the care of long-term survivors. (See  <a class="medical medical_review" href="/d/html/4331.html" rel="external">"Radiation-induced lung injury"</a>.)</p><p class="headingAnchor" id="H369842661"><span class="h2">Fibrosis</span><span class="headingEndMark"> — </span>Pulmonary fibrosis is a dreaded complication of certain chemotherapies, including <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, and <a class="drug drug_general" data-topicid="9206" href="/d/drug information/9206.html" rel="external">carmustine</a>, and radiation treatment. In a small study of 17 children who received carmustine to treat brain neoplasms, 25-year follow-up revealed that nine (53 percent) died of pulmonary fibrosis. Of the eight survivors, follow-up was available on seven patients, who all showed signs of upper zone pulmonary fibrosis [<a href="#rid154">154</a>]. (See  <a class="medical medical_review" href="/d/html/4316.html" rel="external">"Bleomycin-induced lung injury"</a>.)</p><p>Radiation-induced pulmonary fibrosis develops at least 6 to 24 months after exposure to radiation, with patients presenting with progressive dyspnea and cough. In some cases, fibrosis is observed on imaging alone and patients are asymptomatic [<a href="#rid155">155</a>]. Steroids typically are associated with little benefit. The Childhood Cancer Survivor Study (CCSS) demonstrated that patients exposed to chest RT were 4.3 times more likely than their siblings to have pulmonary fibrosis five years post-diagnosis. Chest RT was also associated with a 3.5 percent cumulative incidence of pulmonary fibrosis 20 years postdiagnosis [<a href="#rid156">156</a>]. (See  <a class="medical medical_review" href="/d/html/4331.html" rel="external">"Radiation-induced lung injury"</a>.)</p><p class="headingAnchor" id="H369842667"><span class="h2">Bronchiolitis obliterans syndrome</span><span class="headingEndMark"> — </span>Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication that can be a significant source of morbidity and mortality in patients receiving allogeneic hematopoietic cell transplantation (HCT) [<a href="#rid157">157</a>]. (See  <a class="medical medical_review" href="/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"</a> and  <a class="medical medical_review" href="/d/html/4323.html" rel="external">"Overview of bronchiolar disorders in adults"</a> and  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes"</a>.)</p><p>BOS is a complication seen after allogeneic HCT and is observed in the presence of chronic graft-versus-host disease (GVHD). This syndrome causes airflow obstruction secondary to progressive circumferential fibrosis with eventual scarring of terminal bronchioles [<a href="#rid158">158</a>]. Further details on the etiology and clinical presentation of BOS are discussed separately. (See  <a class="medical medical_review" href="/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Etiology and risk factors'</a> and  <a class="medical medical_review" href="/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Clinical presentation'</a>.)</p><p>Since patients with BOS can present asymptomatically and insidiously, screening pulmonary function testing (PFT) is used to monitor for BOS at various intervals in those post-HCT and those diagnosed with chronic GVHD [<a href="#rid159">159</a>]. The frequency of such screening is discussed separately. (See  <a class="medical medical_review" href="/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease", section on 'Lung'</a>.)</p><p>The diagnosis of BOS can be made conditionally on the basis of PFTs demonstrating increasing airflow limitations, and pulmonary biopsy is generally not needed; a new onset obstructive lung defect typifies BOS [<a href="#rid159">159,160</a>]. In addition to PFTs, a high-resolution computed tomography (CT) is also recommended for evaluation [<a href="#rid159">159</a>]. These and other diagnostic testing for BOS are discussed separately. (See  <a class="medical medical_review" href="/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Evaluation for CLAD'</a>.)</p><p>Long-term survival was initially poor [<a href="#rid161">161</a>] but is improving. Among patients with BOS, two to three-year overall survival ranges from 60 to 75 percent and five-year overall survival ranges from 40 to 50 percent [<a href="#rid162">162</a>]. (See  <a class="medical medical_review" href="/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H1246102"><span class="h2">Pulmonary hypertension</span><span class="headingEndMark"> — </span>Though not as clearly established, there are emerging data that chest RT may be associated with pulmonary hypertension (HTN). Among 498 adult survivors of childhood cancer exposed to anthracyclines or chest RT, 15 percent had an increased tricuspid regurgitant jet velocity. Increased tricuspid regurgitant jet velocity was also present in 25.2 percent of patients exposed to chest RT, and 30.8 percent in patients who received doses greater than 30 gray (Gy). Survivors with increased tricuspid regurgitant jet velocity also had an odds ratio (OR) of 5.2 (95% CI 2.5-11.0) of being limited on a six-minute walk test compared with counterparts with a normal tricuspid regurgitant jet velocity [<a href="#rid163">163</a>]. These findings suggest the possibility of pulmonary vascular damage from chest RT. There are some data to suggest the utility of invasive hemodynamics in survivors with an increased tricuspid regurgitant velocity by echocardiography [<a href="#rid164">164</a>].</p><p>Although the incidence is unclear, pulmonary HTN has been reported in children and adults after HCT [<a href="#rid165">165</a>]. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Pulmonary vascular disease'</a>.)</p><p>Several tyrosine kinase inhibitors (TKI) used in cancer treatment (eg, <a class="drug drug_general" data-topicid="9448" href="/d/drug information/9448.html" rel="external">nilotinib</a>, <a class="drug drug_general" data-topicid="87456" href="/d/drug information/87456.html" rel="external">ponatinib</a>, <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a>, <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a>) are associated with pulmonary arterial HTN. <a class="drug drug_general" data-topicid="8852" href="/d/drug information/8852.html" rel="external">Dasatinib</a> has the strongest evidence for causing drug-induced pulmonary HTN [<a href="#rid166">166</a>]. (See  <a class="medical medical_review" href="/d/html/4336.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Dasatinib'</a>.)</p><p class="headingAnchor" id="H1246108"><span class="h2">Secondary lung cancer</span><span class="headingEndMark"> — </span>RT to the chest increases the risk of subsequent lung cancer. Among 64,782 breast cancer survivors who had surgery, at 10 to 14 years and &gt;15 years from their initial diagnosis, patients who received RT were at a significantly higher relative risk (RR) of lung cancer than those who did not (RR 1.62, 95% CI 1.05-2.54 and RR 1.49, 95% CI 1.05-2.14, respectively) [<a href="#rid167">167</a>]. Other populations who receive chest RT appear to also be at risk; in another study of survivors of Hodgkin lymphoma, those treated with chest RT had an RR of 2.7 to 7 of developing lung cancer [<a href="#rid168">168</a>]. (See  <a class="medical medical_review" href="/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers", section on 'Screening for subsequent primary cancers'</a>.)</p><p class="headingAnchor" id="H369842679"><span class="h2">Monitoring pulmonary function and follow-up</span><span class="headingEndMark"> — </span>For patients suspected of having symptoms attributable to pulmonary toxicity, pulmonary function tests can be used to aid in the diagnosis of subclinical, asymptomatic disease.</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 1713 survivors of childhood cancer, 65.2 percent (95% CI 60.4-69.8) had abnormal pulmonary function tests with the highest prevalence in those treated with lung RT (74.4 percent [95% CI 69.1-79.2], <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> (73.5 percent [95% CI 61.9-82.9], and thoracotomy (53.2 [95% CI 44.1-62]) [<a href="#rid169">169</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study that included 220 five-year childhood cancer survivors who received potentially pulmonary toxic chemotherapy, 44 percent had abnormal pulmonary function tests at a median follow-up of 18 years. Restrictive lung disease and decreased carbon monoxide diffusion capacity were the most common abnormality [<a href="#rid170">170</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term follow-up with spirometry and questionnaires of 1049 testicular cancer survivors showed that 8 percent had restrictive lung disease. In this study, patients treated with a cumulative <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> dose greater than 850 mg and patients treated with cisplatin and pulmonary surgery had increased odds of developing restrictive lung disease compared with patients treated with surgery alone. Interestingly, of the patients diagnosed with restrictive lung disease, only 9.5 percent had self-reported dyspnea and 7.5 percent had prevalent asthma [<a href="#rid171">171</a>].</p><p></p><p>Despite the potential discrepancy between pulmonary function tests and overt clinical symptoms, early identification for pulmonary disease is important given it is a significant cause of mortality in adult survivors. In a CCSS which included 20,483 five-year survivors of childhood cancer, the cumulative mortality at 30 years from diagnosis was 18.1 percent (95% CI, 17.3-18.9) and survivors were 8.8 times more likely to die from a pulmonary cause [<a href="#rid163">163</a>].</p><p class="headingAnchor" id="H369842712"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy and cardiovascular (CV) disease </strong>– Radiation therapy (RT) is associated with an increased risk of CV disease, including coronary atherosclerosis and carotid disease, as well as cardiac structural abnormalities such as valvular and pericardial disease. (See <a class="local">'Effect of cancer therapy on atherosclerosis'</a> above and <a class="local">'Cardiac structural complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer therapy and hypertension (HTN) </strong>– Testicular cancer survivors have an increased risk of HTN, hyperlipidemia, coronary disease, and metabolic syndrome, as do prostate cancer patients undergoing long-term therapy with androgen deprivation therapy (ADT). (See <a class="local">'Hypertension'</a> above and <a class="local">'Androgen deprivation therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although vascular endothelial growth factor (VEGF) signaling pathway inhibitors (antiangiogenic therapy) are strongly associated with HTN and CV dysfunction during therapy, the long-term effects of these agents remain undefined. However, judicious blood pressure control and aggressive CV risk factor modification are important guiding principles. (See <a class="local">'Targeted therapy'</a> above and  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antihypertensive therapy is crucial to manage HTN during certain chemotherapy and those agents known to prevent heart failure (HF) are preferred. (See <a class="local">'Management recommendations for cancer therapy-induced hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myocardial dysfunction </strong>– Several classes of chemotherapy agents used commonly are known to have myocardial dysfunction and HF as important consequences in a growing survivor population (anthracyclines, human epidermal growth factor receptor 2 [HER2] receptor antagonists). (See <a class="local">'Effect of cancer therapy on cardiomyopathy'</a> above and  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a> and  <a class="medical medical_review" href="/d/html/774.html" rel="external">"Cardiotoxicity of trastuzumab and other HER2-targeted agents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prediction models for CV disease </strong>– Models have been developed to predict the risk of HF, ischemic heart disease, and stroke among survivors of childhood cancer. (See <a class="local">'Cardiac risk factor prediction model'</a> above and <a class="local">'Heart failure risk calculator'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance guidelines for cardiovascular disease and cardiomyopathy</strong> – There are available surveillance guidelines for cardiovascular disease and cardiomyopathy in childhood, adolescent, and young adult cancer survivors. (See <a class="local">'Surveillance guidelines for cardiovascular disease'</a> above and <a class="local">'Surveillance guidelines for myocardial dysfunction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of cardiac dysfunction </strong>– Once a patient develops cardiac dysfunction related to chemotherapy, appropriate HF-based therapy should be used promptly. Early discontinuation of cardioprotective HF therapy is not advised. (See <a class="local">'Management of cardiac dysfunction and heart failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer therapy and pulmonary toxicity</strong> – Pulmonary effects of chemotherapy, chest RT, and hematopoietic cell transplant (HCT) can have an insidious onset and devastating consequences. Providers should be aware of conditions that can present years after cancer treatment and are associated with increased mortality. (See <a class="local">'Pulmonary toxicity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diagnostic evaluation can include pulmonary function tests, echocardiograms to assess pulmonary pressures, and chest radiographic imaging in patients who have been exposed to pulmonary toxic chemotherapy or chest RT. (See <a class="local">'Monitoring pulmonary function and follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tobacco cessation </strong>– Cancer survivors who continue to smoke tobacco should be counseled to discontinue tobacco use, as smoking increases the risk of a second malignancy. (See  <a class="medical medical_review" href="/d/html/17024.html" rel="external">"Treatment of alcohol use and smoking for cancer survivors"</a> and  <a class="medical medical_review" href="/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers", section on 'Screening for subsequent primary cancers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lifestyle modifications </strong>– Cancer survivors should also be counseled to engage in a daily exercise regimen to promote CV fitness as well as a heart-healthy diet. (See  <a class="medical medical_review" href="/d/html/14222.html" rel="external">"The roles of diet, physical activity, and body weight in cancer survivors"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Fact Sheet. International Agency for Research on Cancer. Available at: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf (Accessed on March 14, 2019).</li><li class="breakAll">Cancer Facts &amp; Figures 2017. American Cancer Society. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf (Accessed on September 07, 2017).</li><li><a class="nounderline abstract_t">Strongman H, Gadd S, Matthews A, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet 2019; 394:1041.</a></li><li><a class="nounderline abstract_t">Armenian SH, Xu L, Ky B, et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol 2016; 34:1122.</a></li><li><a class="nounderline abstract_t">Bates JE, Howell RM, Liu Q, et al. Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study. J Clin Oncol 2019; 37:1090.</a></li><li><a class="nounderline abstract_t">van Laar M, Feltbower RG, Gale CP, et al. Cardiovascular sequelae in long-term survivors of young peoples' cancer: a linked cohort study. Br J Cancer 2014; 110:1338.</a></li><li><a class="nounderline abstract_t">Scholz-Kreisel P, Spix C, Blettner M, et al. Prevalence of cardiovascular late sequelae in long-term survivors of childhood cancer: A systematic review and meta-analysis. Pediatr Blood Cancer 2017; 64.</a></li><li><a class="nounderline abstract_t">Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013; 31:3673.</a></li><li><a class="nounderline abstract_t">Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007; 25:3991.</a></li><li><a class="nounderline abstract_t">Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368:987.</a></li><li><a class="nounderline abstract_t">van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J Clin Oncol 2016; 34:235.</a></li><li><a class="nounderline abstract_t">Dubec JJ, Munk PL, Tsang V, et al. Carotid artery stenosis in patients who have undergone radiation therapy for head and neck malignancy. Br J Radiol 1998; 71:872.</a></li><li><a class="nounderline abstract_t">Steele SR, Martin MJ, Mullenix PS, et al. Focused high-risk population screening for carotid arterial stenosis after radiation therapy for head and neck cancer. Am J Surg 2004; 187:594.</a></li><li><a class="nounderline abstract_t">King LJ, Hasnain SN, Webb JA, et al. Asymptomatic carotid arterial disease in young patients following neck radiation therapy for Hodgkin lymphoma. Radiology 1999; 213:167.</a></li><li><a class="nounderline abstract_t">van den Bogaard VA, Ta BD, van der Schaaf A, et al. Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures. J Clin Oncol 2017; 35:1171.</a></li><li><a class="nounderline abstract_t">Leerink JM, de Baat EC, Feijen EAM, et al. Cardiac Disease in Childhood Cancer Survivors: Risk Prediction, Prevention, and Surveillance: JACC CardioOncology State-of-the-Art Review. JACC CardioOncol 2020; 2:363.</a></li><li><a class="nounderline abstract_t">Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16:187.</a></li><li><a class="nounderline abstract_t">Wang K, Eblan MJ, Deal AM, et al. Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. J Clin Oncol 2017; 35:1387.</a></li><li><a class="nounderline abstract_t">Protack CD, Bakken AM, Saad WE, et al. Radiation arteritis: a contraindication to carotid stenting? J Vasc Surg 2007; 45:110.</a></li><li><a class="nounderline abstract_t">Moritz MW, Higgins RF, Jacobs JR. Duplex imaging and incidence of carotid radiation injury after high-dose radiotherapy for tumors of the head and neck. Arch Surg 1990; 125:1181.</a></li><li><a class="nounderline abstract_t">Correa CR, Litt HI, Hwang WT, et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 2007; 25:3031.</a></li><li><a class="nounderline abstract_t">Zagar TM, Marks LB. Breast cancer radiotherapy and coronary artery stenosis: location, location, location. J Clin Oncol 2012; 30:350.</a></li><li><a class="nounderline abstract_t">Nilsson G, Holmberg L, Garmo H, et al. Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol 2012; 30:380.</a></li><li><a class="nounderline abstract_t">Witteles RM. Radiation therapy for breast cancer: buyer beware. J Am Coll Cardiol 2011; 57:453.</a></li><li><a class="nounderline abstract_t">Ganatra S, Chatur S, Nohria A. How to Diagnose and Manage Radiation Cardiotoxicity. JACC CardioOncol 2020; 2:655.</a></li><li><a class="nounderline abstract_t">Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007; 50:1435.</a></li><li><a class="nounderline abstract_t">Alfano CM, Ganz PA, Rowland JH, Hahn EE. Cancer survivorship and cancer rehabilitation: revitalizing the link. J Clin Oncol 2012; 30:904.</a></li><li><a class="nounderline abstract_t">McCullough LE, Eng SM, Bradshaw PT, et al. Fat or fit: the joint effects of physical activity, weight gain, and body size on breast cancer risk. Cancer 2012; 118:4860.</a></li><li><a class="nounderline abstract_t">Collier A, Ghosh S, McGlynn B, Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am J Clin Oncol 2012; 35:504.</a></li><li><a class="nounderline abstract_t">Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110:1493.</a></li><li><a class="nounderline abstract_t">Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011; 306:2359.</a></li><li><a class="nounderline abstract_t">Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2020; 382:2197.</a></li><li><a class="nounderline abstract_t">Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 2019; 37:2974.</a></li><li><a class="nounderline abstract_t">Shore ND, Saad F, Cookson MS, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020; 382:2187.</a></li><li><a class="nounderline abstract_t">Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010; 121:833.</a></li><li><a class="nounderline abstract_t">Bhatia N, Santos M, Jones LW, et al. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Circulation 2016; 133:537.</a></li><li><a class="nounderline abstract_t">Margel D, Peer A, Ber Y, et al. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease. J Urol 2019; 202:1199.</a></li><li><a class="nounderline abstract_t">Gong J, Payne D, Caron J, et al. Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer. JACC CardioOncol 2020; 2:553.</a></li><li><a class="nounderline abstract_t">Troeschel AN, Hartman TJ, Jacobs EJ, et al. Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer. J Clin Oncol 2020; 38:2018.</a></li><li><a class="nounderline abstract_t">Narayan V, Ky B. Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention. Annu Rev Med 2018; 69:97.</a></li><li><a class="nounderline abstract_t">Sun L, Parikh RB, Hubbard RA, et al. Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer. JAMA Netw Open 2021; 4:e210070.</a></li><li><a class="nounderline abstract_t">Schindera C, Zürcher SJ, Jung R, et al. Physical fitness and modifiable cardiovascular disease risk factors in survivors of childhood cancer: A report from the SURfit study. Cancer 2021; 127:1690.</a></li><li><a class="nounderline abstract_t">Chow EJ, Chen Y, Hudson MM, et al. Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer. J Clin Oncol 2018; 36:44.</a></li><li><a class="nounderline abstract_t">Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572.</a></li><li><a class="nounderline abstract_t">Mulrooney DA, Armstrong GT, Huang S, et al. Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy: A Cross-sectional Study. Ann Intern Med 2016; 164:93.</a></li><li><a class="nounderline abstract_t">van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012; 30:1429.</a></li><li><a class="nounderline abstract_t">Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013; 128:1927.</a></li><li><a class="nounderline abstract_t">Haddy N, Diallo S, El-Fayech C, et al. Cardiac Diseases Following Childhood Cancer Treatment: Cohort Study. Circulation 2016; 133:31.</a></li><li><a class="nounderline abstract_t">Mueller S, Kline CN, Buerki RA, et al. Stroke impact on mortality and psychologic morbidity within the Childhood Cancer Survivor Study. Cancer 2020; 126:1051.</a></li><li><a class="nounderline abstract_t">Suh E, Stratton KL, Leisenring WM, et al. Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol 2020; 21:421.</a></li><li><a class="nounderline abstract_t">Dixon SB, Liu Q, Chow EJ, et al. Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet 2023; 401:1447.</a></li><li><a class="nounderline abstract_t">Chen Y, Chow EJ, Oeffinger KC, et al. Traditional Cardiovascular Risk Factors and Individual Prediction of Cardiovascular Events in Childhood Cancer Survivors. J Natl Cancer Inst 2020; 112:256.</a></li><li><a class="nounderline abstract_t">Mulrooney DA, Hyun G, Ness KK, et al. Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort. BMJ 2020; 368:l6794.</a></li><li><a class="nounderline abstract_t">Tawfiq E, Selak V, Elwood JM, et al. Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study. Lancet 2023; 401:357.</a></li><li><a class="nounderline abstract_t">Mitchell JD, Cehic DA, Morgia M, et al. Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society. JACC CardioOncol 2021; 3:360.</a></li><li><a class="nounderline abstract_t">Kooijmans EC, Bökenkamp A, Tjahjadi NS, et al. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev 2019; 3:CD008944.</a></li><li><a class="nounderline abstract_t">Travis LB, Beard C, Allan JM, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010; 102:1114.</a></li><li><a class="nounderline abstract_t">Tothill P, Klys HS, Matheson LM, et al. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer 1992; 28A:1358.</a></li><li><a class="nounderline abstract_t">Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355:1075.</a></li><li><a class="nounderline abstract_t">Kirchmair R, Walter DH, Ii M, et al. Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation 2005; 111:2662.</a></li><li><a class="nounderline abstract_t">Jansson T, Persson E. Placental transfer of glucose and amino acids in intrauterine growth retardation: studies with substrate analogs in the awake guinea pig. Pediatr Res 1990; 28:203.</a></li><li><a class="nounderline abstract_t">El-Awady el-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol 2011; 650:335.</a></li><li><a class="nounderline abstract_t">Sagstuen H, Aass N, Fosså SD, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005; 23:4980.</a></li><li><a class="nounderline abstract_t">Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28:4649.</a></li><li><a class="nounderline abstract_t">Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26:5204.</a></li><li><a class="nounderline abstract_t">Mellor HR, Bell AR, Valentin JP, Roberts RR. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci 2011; 120:14.</a></li><li><a class="nounderline abstract_t">Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011.</a></li><li><a class="nounderline abstract_t">Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist 2010; 15:683.</a></li><li><a class="nounderline abstract_t">Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009; 20:1535.</a></li><li><a class="nounderline abstract_t">Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management. JACC CardioOncol 2019; 1:238.</a></li><li><a class="nounderline abstract_t">Abdel-Qadir H, Ethier JL, Lee DS, et al. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev 2017; 53:120.</a></li><li><a class="nounderline abstract_t">Totzeck M, Mincu RI, Mrotzek S, et al. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol 2018; 25:482.</a></li><li><a class="nounderline abstract_t">Waliany S, Sainani KL, Park LS, et al. Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor. JACC CardioOncol 2019; 1:24.</a></li><li><a class="nounderline abstract_t">Chow EJ, Chen Y, Armstrong GT, et al. Underdiagnosis and Undertreatment of Modifiable Cardiovascular Risk Factors Among Survivors of Childhood Cancer. J Am Heart Assoc 2022; 11:e024735.</a></li><li><a class="nounderline abstract_t">Sapkota Y, Li N, Pierzynski J, et al. Contribution of Polygenic Risk to Hypertension Among Long-Term Survivors of Childhood Cancer. JACC CardioOncol 2021; 3:76.</a></li><li><a class="nounderline abstract_t">Simon MS, Hastert TA, Barac A, et al. Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative. Cancer 2021; 127:598.</a></li><li><a class="nounderline abstract_t">James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507.</a></li><li><a class="nounderline abstract_t">Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 70:252.</a></li><li><a class="nounderline abstract_t">Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011; 103:1299.</a></li><li><a class="nounderline abstract_t">Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol 2013; 31:1398.</a></li><li><a class="nounderline abstract_t">McCloskey EV, Hannon RA, Lakner G, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007; 43:2523.</a></li><li><a class="nounderline abstract_t">Blaser BW, Kim HT, Alyea EP 3rd, et al. Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18:575.</a></li><li><a class="nounderline abstract_t">Kagoya Y, Seo S, Nannya Y, Kurokawa M. Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis. Clin Transplant 2012; 26:E168.</a></li><li><a class="nounderline abstract_t">Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87:599.</a></li><li><a class="nounderline abstract_t">Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 2008; 28:1511.</a></li><li><a class="nounderline abstract_t">Bates JE, Shrestha S, Liu Q, et al. Cardiac Substructure Radiation Dose and Risk of Late Cardiac Disease in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 2023; 41:3826.</a></li><li class="breakAll">Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 3.0, 2008. http://www.survivorshipguidelines.org/pdf/XRT%20Reference%20Guide%20v3.0.pdf (Accessed on March 07, 2014).</li><li><a class="nounderline abstract_t">Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017; 35:893.</a></li><li><a class="nounderline abstract_t">Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37:2768.</a></li><li><a class="nounderline abstract_t">Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020; 31:171.</a></li><li><a class="nounderline abstract_t">Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339:b4606.</a></li><li><a class="nounderline abstract_t">Armstrong GT, Joshi VM, Ness KK, et al. Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study. J Am Coll Cardiol 2015; 65:2511.</a></li><li><a class="nounderline abstract_t">Narayan HK, Finkelman B, French B, et al. Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up. Circulation 2017; 135:1397.</a></li><li><a class="nounderline abstract_t">Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290:2831.</a></li><li><a class="nounderline abstract_t">Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003; 42:743.</a></li><li><a class="nounderline abstract_t">van der Pal HJ, van Dijk IW, Geskus RB, et al. Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: a long-term follow-up study. Int J Radiat Oncol Biol Phys 2015; 91:213.</a></li><li><a class="nounderline abstract_t">American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. J Am Soc Echocardiogr 2011; 24:229.</a></li><li><a class="nounderline abstract_t">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57.</a></li><li><a class="nounderline abstract_t">Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011; 117:412.</a></li><li><a class="nounderline abstract_t">Bijl JM, Roos MM, van Leeuwen-Segarceanu EM, et al. Assessment of Valvular Disorders in Survivors of Hodgkin's Lymphoma Treated by Mediastinal Radiotherapy ± Chemotherapy. Am J Cardiol 2016; 117:691.</a></li><li><a class="nounderline abstract_t">Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis 2010; 53:157.</a></li><li><a class="nounderline abstract_t">Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109:3122.</a></li><li><a class="nounderline abstract_t">Little WC, Freeman GL. Pericardial disease. Circulation 2006; 113:1622.</a></li><li><a class="nounderline abstract_t">Khandaker MH, Espinosa RE, Nishimura RA, et al. Pericardial disease: diagnosis and management. Mayo Clin Proc 2010; 85:572.</a></li><li><a class="nounderline abstract_t">Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22:3139.</a></li><li><a class="nounderline abstract_t">Florido R, Daya NR, Ndumele CE, et al. Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. J Am Coll Cardiol 2022; 80:22.</a></li><li><a class="nounderline abstract_t">Paterson DI, Wiebe N, Cheung WY, et al. Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study. JACC CardioOncol 2022; 4:85.</a></li><li><a class="nounderline abstract_t">Hibler E, Tanaka Y, Akhter N, et al. Risk of Incident Heart Failure Among Young Adult Cancer Survivors. J Am Coll Cardiol CardioOnc 2023.</a></li><li><a class="nounderline abstract_t">Jefferies JL, Mazur WM, Howell CR, et al. Cardiac remodeling after anthracycline and radiotherapy exposure in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study. Cancer 2021; 127:4646.</a></li><li><a class="nounderline abstract_t">Reding KW, Cheng RK, Vasbinder A, et al. Lifestyle and Cardiovascular Risk Factors Associated With Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors. JACC CardioOncol 2022; 4:53.</a></li><li><a class="nounderline abstract_t">Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077.</a></li><li><a class="nounderline abstract_t">Kaneko H, Yano Y, Lee H, et al. Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients With Cancer. J Clin Oncol 2023; 41:980.</a></li><li><a class="nounderline abstract_t">Leerink JM, van der Pal HJH, Kremer LCM, et al. Refining the 10-Year Prediction of Left Ventricular Systolic Dysfunction in Long-Term Survivors of Childhood Cancer. JACC CardioOncol 2021; 3:62.</a></li><li><a class="nounderline abstract_t">Chellapandian D, Pole JD, Nathan PC, Sung L. Congestive heart failure among children with acute leukemia: a population-based matched cohort study. Leuk Lymphoma 2019; 60:385.</a></li><li><a class="nounderline abstract_t">Feijen EAML, Font-Gonzalez A, Van der Pal HJH, et al. Risk and Temporal Changes of Heart Failure Among 5-Year Childhood Cancer Survivors: a DCOG-LATER Study. J Am Heart Assoc 2019; 8:e009122.</a></li><li><a class="nounderline abstract_t">Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131:1981.</a></li><li><a class="nounderline abstract_t">Feijen EAM, Leisenring WM, Stratton KL, et al. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. JAMA Oncol 2019; 5:864.</a></li><li><a class="nounderline abstract_t">Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97:2869.</a></li><li><a class="nounderline abstract_t">Upshaw JN, Finkelman B, Hubbard RA, et al. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy. JACC Cardiovasc Imaging 2020; 13:198.</a></li><li><a class="nounderline abstract_t">Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol 2012; 30:1415.</a></li><li><a class="nounderline abstract_t">Sapkota Y, Ehrhardt MJ, Qin N, et al. A Novel Locus on 6p21.2 for Cancer Treatment-Induced Cardiac Dysfunction Among Childhood Cancer Survivors. J Natl Cancer Inst 2022; 114:1109.</a></li><li><a class="nounderline abstract_t">Wang X, Singh P, Zhou L, et al. Genome-Wide Association Study Identifies ROBO2 as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors. J Clin Oncol 2023; 41:1758.</a></li><li><a class="nounderline abstract_t">Bhatia S. Genetics of Anthracycline Cardiomyopathy in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2020; 2:539.</a></li><li><a class="nounderline abstract_t">Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation 2019; 140:31.</a></li><li><a class="nounderline abstract_t">Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008; 49:1486.</a></li><li><a class="nounderline abstract_t">Narayan V, Keefe S, Haas N, et al. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res 2017; 23:3601.</a></li><li><a class="nounderline abstract_t">Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010; 28:1308.</a></li><li><a class="nounderline abstract_t">Border WL, Sachdeva R, Stratton KL, et al. Longitudinal Changes in Echocardiographic Parameters of Cardiac Function in Pediatric Cancer Survivors. JACC CardioOncol 2020; 2:26.</a></li><li><a class="nounderline abstract_t">de Baat EC, Feijen EAM, Reulen RC, et al. Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study. J Clin Oncol 2023; 41:96.</a></li><li><a class="nounderline abstract_t">Chow EJ, Chen Y, Kremer LC, et al. Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol 2015; 33:394.</a></li><li><a class="nounderline abstract_t">Dietz AC, Seidel K, Leisenring WM, et al. Solid organ transplantation after treatment for childhood cancer: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol 2019; 20:1420.</a></li><li><a class="nounderline abstract_t">Ehrhardt MJ, Leerink JM, Mulder RL, et al. Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2023; 24:e108.</a></li><li><a class="nounderline abstract_t">Ehrhardt MJ, Ward ZJ, Liu Q, et al. Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. J Clin Oncol 2020; 38:3851.</a></li><li><a class="nounderline abstract_t">Chow EJ, Aggarwal S, Doody DR, et al. Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. J Clin Oncol 2023; 41:2248.</a></li><li><a class="nounderline abstract_t">de Baat EC, van Dalen EC, Mulder RL, et al. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Child Adolesc Health 2022; 6:885.</a></li><li><a class="nounderline abstract_t">Vaduganathan M, Hirji SA, Qamar A, et al. Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy. JACC CardioOncol 2019; 1:54.</a></li><li><a class="nounderline abstract_t">Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:1977.</a></li><li><a class="nounderline abstract_t">Ewer MS, Von Hoff DD, Benjamin RS. A historical perspective of anthracycline cardiotoxicity. Heart Fail Clin 2011; 7:363.</a></li><li><a class="nounderline abstract_t">Noori A, Lindenfeld J, Wolfel E, et al. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail 2000; 6:115.</a></li><li><a class="nounderline abstract_t">Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55:213.</a></li><li><a class="nounderline abstract_t">Dixon SB, Howell CR, Lu L, et al. Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort. Cancer 2021; 127:458.</a></li><li><a class="nounderline abstract_t">Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114:2474.</a></li><li><a class="nounderline abstract_t">Cardinale D, Colombo A, Cipolla CM. Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy. Curr Treat Options Cardiovasc Med 2008; 10:486.</a></li><li><a class="nounderline abstract_t">Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23:7820.</a></li><li><a class="nounderline abstract_t">Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007; 25:3525.</a></li><li><a class="nounderline abstract_t">Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med 2015; 373:288.</a></li><li><a class="nounderline abstract_t">Haustraete E, Obert J, Diab S, et al. Idelalisib-related pneumonitis. Eur Respir J 2016; 47:1280.</a></li><li><a class="nounderline abstract_t">Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120:617.</a></li><li><a class="nounderline abstract_t">Fosså SD, Gilbert E, Dores GM, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007; 99:533.</a></li><li><a class="nounderline abstract_t">White DA, Stover DE. Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids. Chest 1984; 86:723.</a></li><li><a class="nounderline abstract_t">Uzel I, Ozguroglu M, Uzel B, et al. Delayed onset bleomycin-induced pneumonitis. Urology 2005; 66:195.</a></li><li><a class="nounderline abstract_t">Maher J, Daly PA. Severe bleomycin lung toxicity: reversal with high dose corticosteroids. Thorax 1993; 48:92.</a></li><li><a class="nounderline abstract_t">Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 2001; 13:242.</a></li><li><a class="nounderline abstract_t">Lohani S, O'Driscoll BR, Woodcock AA. 25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood. Chest 2004; 126:1007.</a></li><li><a class="nounderline abstract_t">Williams JP, Johnston CJ, Finkelstein JN. Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction? Curr Drug Targets 2010; 11:1386.</a></li><li><a class="nounderline abstract_t">Mertens AC, Yasui Y, Liu Y, et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer 2002; 95:2431.</a></li><li><a class="nounderline abstract_t">Patriarca F, Skert C, Bonifazi F, et al. Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation. Haematologica 2006; 91:1268.</a></li><li><a class="nounderline abstract_t">Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009; 302:306.</a></li><li><a class="nounderline abstract_t">Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21:389.</a></li><li><a class="nounderline abstract_t">Hildebrandt GC, Fazekas T, Lawitschka A, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011; 46:1283.</a></li><li><a class="nounderline abstract_t">Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9:657.</a></li><li><a class="nounderline abstract_t">Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood 2017; 129:448.</a></li><li><a class="nounderline abstract_t">Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27:2328.</a></li><li><a class="nounderline abstract_t">Armstrong GT, Tolle JJ, Piana R, et al. Exercise right heart catheterization for pulmonary hypertension identified on screening echocardiography in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort. Pediatr Blood Cancer 2018; 65.</a></li><li><a class="nounderline abstract_t">Dandoy CE, Hirsch R, Chima R, et al. Pulmonary hypertension after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19:1546.</a></li><li><a class="nounderline abstract_t">McGee M, Whitehead N, Martin J, Collins N. Drug-associated pulmonary arterial hypertension. Clin Toxicol (Phila) 2018; 56:801.</a></li><li><a class="nounderline abstract_t">Roychoudhuri R, Evans H, Robinson D, Møller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 2004; 91:868.</a></li><li><a class="nounderline abstract_t">Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol 2005; 6:773.</a></li><li><a class="nounderline abstract_t">Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013; 309:2371.</a></li><li><a class="nounderline abstract_t">Mulder RL, Thönissen NM, van der Pal HJ, et al. Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer. Thorax 2011; 66:1065.</a></li><li><a class="nounderline abstract_t">Haugnes HS, Aass N, Fosså SD, et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 2009; 27:2779.</a></li></ol></div><div id="topicVersionRevision">Topic 17017 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Fact Sheet. International Agency for Research on Cancer. Available at: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf (Accessed on March 14, 2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cancer Facts &amp; Figures 2017. American Cancer Society. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf (Accessed on September 07, 2017).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31443926" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26834065" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30860946" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24504369" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cardiovascular sequelae in long-term survivors of young peoples' cancer: a linked cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28205419" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of cardiovascular late sequelae in long-term survivors of childhood cancer: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24002505" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17577017" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23484825" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk of ischemic heart disease in women after radiotherapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26573075" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9828801" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Carotid artery stenosis in patients who have undergone radiation therapy for head and neck malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15135672" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Focused high-risk population screening for carotid arterial stenosis after radiation therapy for head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10540657" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Asymptomatic carotid arterial disease in young patients following neck radiation therapy for Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28095159" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34396245" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cardiac Disease in Childhood Cancer Survivors: Risk Prediction, Prevention, and Surveillance: JACC CardioOncology State-of-the-Art Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25601342" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28113017" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17210394" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Radiation arteritis: a contraindication to carotid stenting?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205173" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Duplex imaging and incidence of carotid radiation injury after high-dose radiotherapy for tumors of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634481" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22203762" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Breast cancer radiotherapy and coronary artery stenosis: location, location, location.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22203772" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Distribution of coronary artery stenosis after radiation for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21251586" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Radiation therapy for breast cancer: buyer beware.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34396277" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : How to Diagnose and Manage Radiation Cardiotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919562" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Early breast cancer therapy and cardiovascular injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22355063" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cancer survivorship and cancer rehabilitation: revitalizing the link.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733561" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fat or fit: the joint effects of physical activity, weight gain, and body size on breast cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21297430" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17657815" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22147380" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469184" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31329516" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469183" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124128" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26831435" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31188734" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34396266" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32250715" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29414258" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33625512" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33405260" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Physical fitness and modifiable cardiovascular disease risk factors in survivors of childhood cancer: A report from the SURfit study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29095680" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17035650" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Chronic health conditions in adult survivors of childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26747086" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy: A Cross-sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473161" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : High risk of symptomatic cardiac events in childhood cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24081971" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26487757" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cardiac Diseases Following Childhood Cancer Treatment: Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31809558" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Stroke impact on mortality and psychologic morbidity within the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32066543" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37030315" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31161223" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Traditional Cardiovascular Risk Factors and Individual Prediction of Cardiovascular Events in Childhood Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31941657" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36702148" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34604797" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30855726" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20585105" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Testicular cancer survivorship: research strategies and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1515251" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10744098" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897348" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2235115" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Placental transfer of glucose and amino acids in intrauterine growth retardation: studies with substrate analogs in the awake guinea pig.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21034734" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16051950" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Blood pressure and body mass index in long-term survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855830" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838713" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177772" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cardiotoxicity associated with targeting kinase pathways in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18083403" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547589" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19474115" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32206762" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28104567" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29376753" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34396159" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35674343" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Underdiagnosis and Undertreatment of Modifiable Cardiovascular Risk Factors Among Survivors of Childhood Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33842896" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Contribution of Polygenic Risk to Hypertension Among Long-Term Survivors of Childhood Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33151547" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24352797" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28315732" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21743022" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23358971" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18029171" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21839706" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22507357" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836291" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Changes in body composition during androgen deprivation therapy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19025432" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37307512" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cardiac Substructure Radiation Dose and Risk of Late Cardiac Disease in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37307512" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Cardiac Substructure Radiation Dose and Risk of Late Cardiac Disease in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918725" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27567406" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31959335" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996459" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26065990" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28104715" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657067" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12932613" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Asymptomatic cardiac disease following mediastinal irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25442333" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: a long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21338862" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24603191" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20858859" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26772441" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Assessment of Valvular Disorders in Survivors of Hodgkin's Lymphoma Treated by Mediastinal Radiotherapy±Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20728703" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Evaluation and management of pericardial effusion in patients with neoplastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15226229" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567581" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pericardial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20511488" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Pericardial disease: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284266" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35772913" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35492824" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Incident Cardiovascular Disease Among Adults With Cancer: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Risk of Incident Heart Failure Among Young Adult Cancer Survivors</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34411296" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Cardiac remodeling after anthracycline and radiotherapy exposure in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35492810" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Lifestyle and Cardiovascular Risk Factors Associated With Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10760308" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36075006" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients With Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34396306" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Refining the 10-Year Prediction of Left Ventricular Systolic Dysfunction in Long-Term Survivors of Childhood Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29966479" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Congestive heart failure among children with acute leukemia: a population-based matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30595059" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Risk and Temporal Changes of Heart Failure Among 5-Year Childhood Cancer Survivors: a DCOG-LATER Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25948538" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30703192" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12767102" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31542526" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22124095" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35698272" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : A Novel Locus on 6p21.2 for Cancer Treatment-Induced Cardiac Dysfunction Among Childhood Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36508697" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Genome-Wide Association Study Identifies ROBO2 as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33364618" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Genetics of Anthracycline Cardiomyopathy in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30987448" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18608873" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28196874" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142603" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32719829" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Longitudinal Changes in Echocardiographic Parameters of Cardiac Function in Pediatric Cancer Survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36075007" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25287823" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Individual prediction of heart failure among childhood cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31471158" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Solid organ transplantation after treatment for childhood cancer: a retrospective cohort analysis from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37052966" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32795226" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36669148" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36174614" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33083790" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19324967" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21749888" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : A historical perspective of anthracycline cardiotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10908085" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Beta-blockade in adriamycin-induced cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20117401" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33108003" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101852" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19026179" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16258084" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17687157" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26176400" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26917607" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Idelalisib-related pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502668" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Bleomycin-induced pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17405998" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Noncancer causes of death in survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6207992" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15992893" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Delayed onset bleomycin-induced pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7679525" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Severe bleomycin lung toxicity: reversal with high dose corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11429481" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Radiation-induced and chemotherapy-induced pulmonary injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364795" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : 25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20583979" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12436452" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16956831" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19602690" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25529383" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21441964" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14569562" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27856461" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332714" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28843055" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Exercise right heart catheterization for pulmonary hypertension identified on screening echocardiography in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23891748" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Pulmonary hypertension after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29508628" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Drug-associated pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292931" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Radiation-induced malignancies following radiotherapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16198983" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Lung cancer after treatment for Hodgkin's lymphoma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23757085" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Clinical ascertainment of health outcomes among adults treated for childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21803931" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414680" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Pulmonary function in long-term survivors of testicular cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
